Partner David Rosen was quoted in a Modern Healthcare article, “New Safety Threats Identified in One-Third of Drugs Post-Approval,” covering why these statistics make sense, and covering FDA user fees as they relate to the issue.
Rosen explained he doesn’t think “the user fee time deadlines really have an impact [on the issue]; it doesn’t mean that the FDA is putting out drugs that are less safe. The FDA takes safety very seriously and does the best job it can in making sure labels show the proper risk and benefits and are updated.”
Rosen explained he doesn’t think “the user fee time deadlines really have an impact [on the issue]; it doesn’t mean that the FDA is putting out drugs that are less safe. The FDA takes safety very seriously and does the best job it can in making sure labels show the proper risk and benefits and are updated.”
People
Related News
June 26, 2025
In the News
Alejandro Gomez-Strozzi on Mexico-US Auto Parts Trade – 'Going forward, there is nothing but integration'
Foley & Lardner lLP partner Alejandro Gómez-Strozzi shared insights on foreign direct investment around Mexico's automotive parts sector in the El Economista article, "Efecto Trump pega más a IED en autopartes que en autos y camiones."
June 25, 2025
In the News
Jocelyn Lavallo Explores Nuclear's Emerging Role in Project Finance
Foley & Lardner LLP partner Jocelyn Lavallo examined the increasing relevance of advanced nuclear technologies in the evolving clean energy landscape in her Environment+Energy Leader article, "Nuclear’s Emerging Role in Project Finance: A Cross-Technology Perspective."
June 25, 2025
In the News
Kyle Faget Comments on AI, User Fees Ahead of MDUFA Negotiations
Foley & Lardner LLP partner Kyle Faget weighed in on the role of user fees and artificial intelligence as stakeholders prepare for the next Medical Device User Fee Amendments (MDUFA) reauthorization in the Medtech Insight article, "Will Kennedy And Makary Come To Terms On User Fees During Next Round Of MDUFA Negotiations?"